CytomX Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
About CytomX Therapeutics
Pharmaceutical Preparations, SIC 2834
CytomX is a clinical-stage biopharmaceutical company that develops conditionally activated biologic therapies for cancer treatment. Its PROBODY platform designs biologics that stay inactive in healthy tissue and activate in tumor microenvironments through protease cleavage. The pipeline includes antibody-drug conjugates, T-cell engagers, cytokines, and messenger RNA. Its lead investigational programs include varsetatug masetecan, an antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine for advanced melanoma. The company collaborates with pharmaceutical partners, including Amgen, Bristol Myers Squibb, Astellas, Regeneron, and Moderna, and targets oncology patient populations.
Regarding operational scale, more than 500 patients have received treatment with the company's candidate therapies across multiple clinical trials. In addition, CytomX holds a patent portfolio containing at least 245 granted patents and at least 300 pending patent applications as of January 2026. The provided text does not state the location of the company's headquarters, nor does it disclose geographic details regarding its corporate offices or operational facilities.
Summary of the business section of CytomX Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CytomX Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 151 Oyster Point Blvd., Suite 400 94080
- Phone
- (650) 515-3185
- Employees
- 69, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- CTMX
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2015
- Shares outstanding
- 218M, Jul 31, 2026
- Public float
- $372.30M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1501989
- CUSIP
- 23284F105
- ISIN
- US23284F1057
- LEI
- 5493004VW2FW0QLL3345
- EIN
- 27-3521219
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean A. McCarthy | CEO, Director | 2,253,129 |
| Alejandra Carvajal | Chief Legal Officer | 100,000 |
| Christopher Ogden | Chief Financial Officer | 295,324 |
| Marcia Belvin | SVP, Chief Scientific Officer | 300,760 |
| Yu-Waye Chu | Chief Medical Officer | 189,446 |
| Rachael Lester | Chief Business Officer | 20,000 |
| Lloyd A. Rowland | General Counsel | 120,594 |
| Charles S. Fuchs | Director | – |
| Halley E. Gilbert | Director | – |
| Matthew P. Young | Director | – |
| Alan Ashworth | Director | – |
| James R. Meyers | Director | – |
| Elaine V. Jones | Director | 5,142 |
| Zhen Su | Director | – |
| Mani Mohindru | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Sean A. McCarthy, D. Phil. | $4.74M | $10.64M | $1.89M | $266 | – |
| FY2024 Sean A. McCarthy, D. Phil. | $1.75M | $1.06M | $861.32K | $64 | – |
| FY2023 Sean A. McCarthy, D. Phil. | $2.61M | $519.37K | $1.13M | $97 | – |
| FY2022 Sean A. McCarthy, D. Phil. | $3.01M | $671.92K | $1.38M | $37 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 69 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 26, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 17, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 8, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 6, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |